Amyris, an integrated synthetic biology and industrial biotechnology company, has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for $12.3 million from the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to advance innovative pharmaceutical manufacturing in the U.S.
 
Using Amyris’ advanced technology in organism engineering, advanced precision fermentation, synthetic chemistry, process expertise, and manufacturing, Amyris aims to develop up to three small molecule drugs over the next two years – all of which are on the FDA drug shortage list.
 
Based on the achievement of technology development and other milestones, IBMSC and Amyris will jointly decide which drug targets to advance to sample production. During the agreement term, Amyris will explore partnerships with GMP-manufacturing capabilities and market access to bring fully developed drugs to market.
 
“Amyris has consistently pushed the boundaries of what is possible in industrial biotechnology,” said Kathy Fortmann, CEO of Amyris. “With our strong focus on cutting-edge science and automation, the company has developed a robust pipeline of innovative products and technologies, and this IBMSC funding will accelerate our R&D efforts to bring active pharmaceutical ingredients to market, with a focus on delivering impactful outcomes.”
 
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Center for Industrial Base Management and Supply Chain (IBMSC), under Other Transaction Authority Agreement number #75A50123D00003.